Medicinal cannabis improves quality of life and symptom control in advanced cancer patients
This Phase I/II double-blind, randomized controlled trial evaluates the safety, tolerability, and impact of medicinal cannabis on quality of life and symptom control in advanced cancer patients. The Phase II component specifically measures outcomes including pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden using validated instruments.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Medicinal cannabis improves quality of life and symptom control in advanced cancer patients The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Medicinal cannabis improves quality of life and symptom control in advanced cancer patients
This conclusion is most relevant to: People with advanced cancer.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Phase I/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol. (Clinical therapeutics, 2026) —
How It Works
The proposed biological pathway:
- ▸Medicinal cannabis interacts with endocannabinoid system
- ▸Modulates neurotransmitter release
- ▸Reduces inflammation and pain signaling
- ▸Improves symptom burden and quality of life
Who Might Benefit
Evidence fit by population:
- ▸People with advanced cancer
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Abstract does not report final results or effect sizes
- ▸Phase I open-label design may introduce bias
- ▸Protocol adaptations for inclusivity may affect generalizability
Frequently Asked Questions
What is the purpose of the RESONANCE trial?▼
The trial aims to evaluate the safety, tolerability, and impact of medicinal cannabis on quality of life and symptom control in advanced cancer patients.
What symptoms are being measured in this study?▼
Symptoms measured include pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden.
Is this a randomized controlled trial?▼
Yes, the Phase II component is a double-blind, randomized clinical trial.
What is the significance of this research?▼
It aims to provide high-quality evidence to inform clinical practice and reduce decisional uncertainty for prescribers and patients regarding medicinal cannabis use in advanced cancer care.
References
- 1.Wong AK, McMahon WR, Grobler A, Wilson C, Martin J, Galettis P, Mitchell P, Le B, Philip J, Gan H, Cebon J. “Phase I/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol..” Clinical therapeutics, 2026. PMID: 42476829 DOI: 10.1016/j.clinthera.2026.06.018